- Product Details
Keywords
- Indobufen
- 63610-08-2
- 99% purity
Quick Details
- ProName: Indobufen
- CasNo: 63610-08-2
- Molecular Formula: C18H17NO3
- Appearance: powder
- Application: intermediate
- DeliveryTime: in stock
- PackAge: According to the need of packing
- Port: Shanghai
- ProductionCapacity: 100 Kilogram/Month
- Purity: 99% purity
- Storage: Keep in dark place,Sealed in dry,Room ...
- Transportation: air,sea,courier
- LimitNum: 1 Gram
- Grade: Industrial Grade,Pharma Grade,Electron...
Superiority
Product Name: Indobufen
Synonyms: 1-Oxo-2-[p-[(α-ethyl)carboxyMethyl]phenyl]isoindoline;2-[p-(1-Oxo-2-isoindolinyl)phenyl]butyric Acid;K 2930;(+-)-butyricaci;1-oxo-2-(p-((alpha-ethyl)carboxymethyl)phenyl)isoindoline;4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl)-alpha-ethyl-benzeneaceticacid;2-[4-(1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PHENYL]-BUTYRIC ACID;lndobufen
CAS: 63610-08-2
MF: C18H17NO3
MW: 295.34
EINECS: 264-364-4
Product Categories: Amines;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
Mol File: 63610-08-2.mol
Details
Melting point 182-184°
Boiling point 518.1±50.0 °C(Predicted)
density 1.275±0.06 g/cm3(Predicted)
storage temp. Keep in dark place,Sealed in dry,Room Temperature
pka 4.39±0.10(Predicted)
CAS DataBase Reference 63610-08-2(CAS DataBase Reference)
EPA Substance Registry System Benzeneacetic acid, 4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-.alpha.-ethyl- (63610-08-2)
Description Indobufen is a platelet aggregation inhibitor related to the antiinflammatory agent indoprofen. It has shown clinical efficacy in peripheral artery disease, in prevention of deep vein thrombosis after myocardial infarction, and in blocking excercise-induced increase in platelet aggregation in angina patients.
Originator Erbamont (Italy)
Uses Indobufen is a platelet aggregation inhibitor. Indobufen is the anticoagulant drug and platelet aggregation inhibitor, which has anti-inflammatory analgesic effect. Indobufen is used as an antithrombotic.
Brand name IBUSTRIN
Clinical Use A reversible but very potent inhibitor of platelet COX-1 activity, was shown to have comparable clinical efficacy to that of aspirin in prevention of DVT after myocardial infarction and in blocking exercise-induced increase in platelet aggregation. In the secondary prevention of thromboembolic events, 100 or 200 mg of indobufen twice daily is as effective as warfarin or aspirin in patients with or without atrial fibrillation. Currently, indobufen is only available for routine clinical use in Europe.